Jun 16, 2015
BioCardia, Inc. Files Registration Statement for Proposed Initial Public Offering
Nov 11, 2014
BioCardia®, Inc. Announces FDA Acceptance of Phase III Clinical Trial Protocol Studying Bone Marrow-Derived Cell Therapy for Heart Failure Patients
Sep 15, 2014
CellProThera® and BioCardia® Partner on Phase II Trial to Study CellProThera’s Protheracytes® CD34+ Cells as Delivered by BioCardia’s Helix™ Transendocardial Delivery System
May 19, 2014
Phase II STOP-HF Trial Shows Excellent Safety Profile, Supports Efficacy for Juventas JVS-100 as Delivered by BioCardia® Helix™ Transendocardial Delivery System
May 7, 2014
RECARDIO Clinical Trial Doses First Patient
March 17, 2014
BioCardia® Receives CE Mark for Morph AccessPro™ Steerable Introducer
We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells.
These programs are enabled by the Company's Helix™ transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.